Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) shares were down 8% during mid-day trading on Tuesday . The stock traded as low as $18.78 and last traded at $18.88. Approximately 148,125 shares changed hands during mid-day trading, a decline of 22% from the average daily volume of 188,809 shares. The stock had previously closed at $20.52.
Analyst Ratings Changes
ORKA has been the topic of a number of research analyst reports. Leerink Partners assumed coverage on shares of Oruka Therapeutics in a report on Tuesday, September 17th. They set an "outperform" rating and a $44.00 price objective on the stock. Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a research note on Friday, September 13th. They set a "buy" rating and a $40.00 price target on the stock. TD Cowen began coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They issued a "buy" rating for the company. Lifesci Capital assumed coverage on Oruka Therapeutics in a research report on Monday, September 16th. They issued an "outperform" rating and a $41.00 price objective on the stock. Finally, Stifel Nicolaus initiated coverage on Oruka Therapeutics in a research report on Friday, October 11th. They set a "buy" rating and a $49.00 target price for the company. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $43.17.
View Our Latest Report on Oruka Therapeutics
Oruka Therapeutics Price Performance
The business has a 50-day moving average price of $22.54. The firm has a market capitalization of $664.63 million, a PE ratio of -3.03 and a beta of 0.81.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Franklin Resources Inc. acquired a new stake in Oruka Therapeutics during the 3rd quarter valued at $17,661,000. Geode Capital Management LLC acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter worth about $343,000. Frazier Life Sciences Management L.P. bought a new stake in shares of Oruka Therapeutics during the 3rd quarter worth about $11,699,000. Wellington Management Group LLP acquired a new position in Oruka Therapeutics in the 3rd quarter valued at about $2,013,000. Finally, RTW Investments LP acquired a new position in Oruka Therapeutics in the 3rd quarter valued at about $45,359,000. 56.44% of the stock is owned by institutional investors and hedge funds.
Oruka Therapeutics Company Profile
(
Get Free Report)
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products.
Read More
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
